Literature DB >> 30135250

APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.

Raymond J Cho1, Ludmil B Alexandrov2, Nicoline Y den Breems3, Velina S Atanasova4, Mehdi Farshchian4, Elizabeth Purdom5, Tran N Nguyen6, Cristian Coarfa7, Kimal Rajapakshe7, Marco Prisco4, Joya Sahu4, Patrick Tassone8, Evan J Greenawalt4, Eric A Collisson9,10, Wei Wu9,10,11, Hui Yao12, Xiaoping Su12, Christina Guttmann-Gruber13, Josefina Piñón Hofbauer13, Raabia Hashmi4, Ignacia Fuentes14,15, Stephen C Benz16, Justin Golovato17, Erik A Ehli18, Christel M Davis18, Gareth E Davies18, Kyle R Covington19, Dedee F Murrell20, Julio C Salas-Alanis21, Francis Palisson14,22, Anna L Bruckner23, William Robinson24, Cristina Has25, Leena Bruckner-Tuderman25, Matthias Titeux26,27, Marcel F Jonkman28, Elham Rashidghamat29, Su M Lwin29, Jemima E Mellerio29, John A McGrath29, Johann W Bauer13, Alain Hovnanian26,27, Kenneth Y Tsai6, Andrew P South30.   

Abstract

Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin and mucous membrane fragility disorder complicated by early-onset, highly malignant cutaneous squamous cell carcinomas (SCCs). The molecular etiology of RDEB SCC, which arises at sites of sustained tissue damage, is unknown. We performed detailed molecular analysis using whole-exome, whole-genome, and RNA sequencing of 27 RDEB SCC tumors, including multiple tumors from the same patient and multiple regions from five individual tumors. We report that driver mutations were shared with spontaneous, ultraviolet (UV) light-induced cutaneous SCC (UV SCC) and head and neck SCC (HNSCC) and did not explain the early presentation or aggressive nature of RDEB SCC. Instead, endogenous mutation processes associated with apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like (APOBEC) deaminases dominated RDEB SCC. APOBEC mutation signatures were enhanced throughout RDEB SCC tumor evolution, relative to spontaneous UV SCC and HNSCC mutation profiles. Sixty-seven percent of RDEB SCC driver mutations was found to emerge as a result of APOBEC and other endogenous mutational processes previously associated with age, potentially explaining a >1000-fold increased incidence and the early onset of these SCCs. Human papillomavirus-negative basal and mesenchymal subtypes of HNSCC harbored enhanced APOBEC mutational signatures and transcriptomes similar to those of RDEB SCC, suggesting that APOBEC deaminases drive other subtypes of SCC. Collectively, these data establish specific mutagenic mechanisms associated with chronic tissue damage. Our findings reveal a cause for cancers arising at sites of persistent inflammation and identify potential therapeutic avenues to treat RDEB SCC.
Copyright © 2018 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30135250     DOI: 10.1126/scitranslmed.aas9668

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  33 in total

1.  Identification of Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa-Associated Squamous Cell Carcinoma.

Authors:  Velina S Atanasova; Celine Pourreyron; Mehdi Farshchian; Michael Lawler; Christian A Brown; Stephen A Watt; Sheila Wright; Michael Warkala; Christina Guttmann-Gruber; Josefina Piñón Hofbauer; Ignacia Fuentes; Marco Prisco; Elham Rashidghamat; Cristina Has; Julio C Salas-Alanis; Francis Palisson; Alain Hovnanian; John A McGrath; Jemima E Mellerio; Johann W Bauer; Andrew P South
Journal:  Clin Cancer Res       Date:  2019-03-07       Impact factor: 12.531

2.  Toward treatment and cure of epidermolysis bullosa.

Authors:  Jouni Uitto
Journal:  Proc Natl Acad Sci U S A       Date:  2019-12-11       Impact factor: 11.205

3.  MAB21L4 Deficiency Drives Squamous Cell Carcinoma via Activation of RET.

Authors:  Ankit Srivastava; Cristina Tommasi; Dane Sessions; Angela Mah; Tomas Bencomo; Jasmine M Garcia; Tiffany Jiang; Michael Lee; Joseph Y Shen; Lek Wei Seow; Audrey Nguyen; Kimal Rajapakshe; Cristian Coarfa; Kenneth Y Tsai; Vanessa Lopez-Pajares; Carolyn S Lee
Journal:  Cancer Res       Date:  2022-09-02       Impact factor: 13.312

4.  Pan-cancer analysis of mutations in open chromatin regions and their possible association with cancer pathogenesis.

Authors:  Chie Kikutake; Mikita Suyama
Journal:  Cancer Med       Date:  2022-04-13       Impact factor: 4.711

Review 5.  Unraveling cancer lineage drivers in squamous cell carcinomas.

Authors:  Yinglu Guan; Guan Wang; Danielle Fails; Priyadharsini Nagarajan; Yejing Ge
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

Review 6.  Notch-ing up knowledge on molecular mechanisms of skin fibrosis: focus on the multifaceted Notch signalling pathway.

Authors:  Angelo Giuseppe Condorelli; May El Hachem; Giovanna Zambruno; Alexander Nystrom; Eleonora Candi; Daniele Castiglia
Journal:  J Biomed Sci       Date:  2021-05-09       Impact factor: 8.410

Review 7.  Impaired Wound Healing, Fibrosis, and Cancer: The Paradigm of Recessive Dystrophic Epidermolysis Bullosa.

Authors:  Grace Tartaglia; Qingqing Cao; Zachary M Padron; Andrew P South
Journal:  Int J Mol Sci       Date:  2021-05-12       Impact factor: 5.923

8.  Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: a 28-year Retrospective Study.

Authors:  Susan J Robertson; Elizabeth Orrin; Manpreet K Lakhan; Gavin O'Sullivan; Jessie Felton; Alistair Robson; Danielle T Greenblatt; Catina Bernardis; John A McGrath; Anna E Martinez; Jemima E Mellerio
Journal:  Acta Derm Venereol       Date:  2021-08-24       Impact factor: 3.875

9.  Genetic Predisposition to Numerous Large Ulcerating Basal Cell Carcinomas and Response to Immune Therapy.

Authors:  Bahar Dasgeb; Youssefian Leila; Amir Hossein Saeidian; Jun Kang; Wenyin Shi; Elizabeth Shoenberg; Adam Ertel; Paolo Fortina; Hassan Vahidnezhad; Jouni Uitto
Journal:  Int J Dermatol Venereol       Date:  2021-06-08

10.  The landscape of driver mutations in cutaneous squamous cell carcinoma.

Authors:  Darwin Chang; A Hunter Shain
Journal:  NPJ Genom Med       Date:  2021-07-16       Impact factor: 8.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.